Pharmacoeconomics of mild cognitive impairment
Anders Wimo,
Bengt Winblad,
Anders Wimo
Division of Geriatric Medicine, Neurotec, Karolinska Institutet, Stockholm, Sweden
Search for more papers by this authorBengt Winblad
Division of Geriatric Medicine, Neurotec, Karolinska Institutet, Stockholm, Sweden
Search for more papers by this authorAnders Wimo,
Bengt Winblad,
Anders Wimo
Division of Geriatric Medicine, Neurotec, Karolinska Institutet, Stockholm, Sweden
Search for more papers by this authorBengt Winblad
Division of Geriatric Medicine, Neurotec, Karolinska Institutet, Stockholm, Sweden
Search for more papers by this authorBengt Winblad, Division of Geriatric Medicine,Neurotec, Huddinge Hospital B84, S-141 86 Huddinge, Sweden
e-mail: [email protected]
Abstract
There is little written about the pharmacoeconomics of mild cognitive impairment (MCI), particularly with regard to intervention. The aim of the paper is to highlight methodological issues and to present some results that are of importance when drug interventions of MCI are discussed. There is a relationship between severity of dementia and costs, but to what extent such results can be extrapolated to MCI is not known. Even if it is logical to consider a postponement of the shift from MCI to dementia as cost effective, this statement must be proven, particularly in light of the insufficient knowledge about the effects of antidementia drugs on survival. From the Kungsholmen project in Sweden, there are indications that the postponement between MCI and manifest dementia may result in short-term benefits (a few years) of about SEK50 000 (US$5300).
References
- 1 Lubeck D, Mazonson P et al. The potential impact of tacrine on expenditures for Alzheimer's disease. Med Interface 1994; 7: 130–8.
- 2 O'Brien B, Goeree R et al. Economic evaluation of donepexil in the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 1999; 47: 570–8.
- 3 Neumann P, Hermann R, Kuntz K. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999; 52: 1138–45.
- 4
Stewart A,
Phillips R,
Dempsey G.
Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years therapy using donepezil.
Int J Geriatr Psychiat
1998; 13: 445–53.
10.1002/(SICI)1099-1166(199807)13:7<445::AID-GPS794>3.0.CO;2-E CAS PubMed Web of Science® Google Scholar
- 5 Wimo A, Karlsson G et al. Treatment of Alzheimer's disease with tacrine – a cost analysis model. Alzheimer Dis Assoc Disord 1997; 11: 191–200.
- 6 Palmer K, Jelic V, Winblad B. Preface: mild cognitive impairment. Acta Neurol Scand 2003; 107(Suppl. 179): 5–6.
- 7 Palmer K, Fratiglioni L, Winblad B. What is mild cognitive impairment? Variations in definitions and evolution of nondemented persons with cognitive impairment. Acta Neurol Scand 2003; 107(Suppl. 179): 14–20.
- 8 Winblad B, Hill S et al. Issues in the economic evaluation of treatments for dementia. Alzheimer Dis Assoc Disord 1997; 11: 39–45.
- 9 Drummond M, Stoddart GL, Torrance GEW, O'Brien B. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press 1997.
- 10 Folstein MF, Folstein SE, McHugh PR. ‘Mini-Mental’ State. A practical method for grading the cognitive state of patients for the clinician. Psychiatr Res 1975; 12: 189–98.
- 11 Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis 1987; 40: 593–600.
- 12 Nourhashemi F, Gillette-Guyonnet S, Andrieu S et al. Alzheimer disease: protective factors. Am J Clin Nutr 2000; 71: 643S–9S.
- 13 Meyer JS, Rauch G, Rauch RA et al. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Neurobiol Aging 2000; 21: 161–9.
- 14 Thal L, Carta A, Doody D et al. Prevention protocols in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997; 11 (Suppl. 3): 46–9.
- 15 Agüero Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B. Prognostic factors in very old demented adults: a seven-year follow-up from a population-based survey in Stockholm. J Am Ger Soc 1998; 46: 444–52.
- 16 Fries JF. Aging, natural death and the compression of morbidity. NEJM 1980; 61: 130–5.
- 17
Olshansky SJ,
Rudberg MA,
Carnes BA,
Cassel CK,
Brody JA.
Trading off longer life for worsening health: The expansion of morbidity hypothesis.
J Aging Health
1991; 3: 194–216.
10.1177/089826439100300205 Google Scholar
- 18 Manton KG, Stallard E, Corder L. Changes in morbidity and chronic disability in the U.S elderly population: Evidence from the 1982, 1984 and 1989 National Long Term Care Surveys. J Gerontol B Psychol Sci Soc Sci 1995; 50B: S194–204.
- 19 Ritchie K, Robine JM, Letenneur L, Dartigues JF. Dementia-free life expectancy in France. Am J Public Health 1994; 84: 232–6.
- 20 Thompson SG, Barber JA. How should cost data in pragmatic randomized trials be analysed? BMJ 2000; 320: 1197–200.
- 21 Leber P. Slowing the progression of Alzheimer's Disease: methodological issues. Alzheimer Dis Assoc Disord 1997; 11(Suppl. 5): 510–21.
- 22 Sonnenberg F. Modeling disease progression with Markov Models. In: A Wimo et al., eds. The health economics of dementia. Chichester: Wiley, 1998: 171–96.
- 23 Jönsson L, Lindgren P, Wimo A et al. Costs of MMSE-related cognitive impairment. Pharmacoeconomics 1999; 16: 409–16.
- 24 Ernst R, Hay J et al. Cognitive function and the costs of Alzheimer's disease. Arch Neurol 1995; 54: 687–93.
- 25 Hux M, O'Brien B et al. Relation between severity of Alzheimer's disease and costs of caring. CMAJ 1998; 159: 457–65.
- 26 Souêtre E, Qing W et al. Economic analysis of Alzheimer's disease in outpatients: impact of symptom severity. Int Psychogeriatr 1995; 7: 115–22.
- 27 Schulenberg J, Schulenberg I et al. Cost of treatment and cost of care for Alzheimer's disease in Germany. In: A Wimo et al., eds. The health economics of dementia. Chichester: Wiley, 1998.
- 28 Jönsson L, Jönsson B, Wimo A, Whitehouse P, Winblad B. Second International Pharmacoeconomic Conference on Alzheimer's Disease. Report and summary. Alzheimer Dis Assoc Disord 2000; 14: 137–40.
- 29 Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpga-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997; 336: 1216–22.
- 30
Wimo A,
Karlsson G
et al.
Cost of illness due to dementia in Sweden.
Int J Geriatric Psychiatry
1997; 12: 857–61.
10.1002/(SICI)1099-1166(199708)12:8<857::AID-GPS653>3.0.CO;2-5 PubMed Web of Science® Google Scholar
- 31 Holmes J, Pugner K et al. Managing Alzheimer's disease: the cost of care per patient. Br J Care Manage 1998; 4: 332–7.
- 32 Wimo A, Von Strauss E, Nordberg G, Johansson L. Time spent in informal and formal care giving for persons with dementia in Sweden. Health Policy 2002; 61(3): 255–68.
